10x Genomics, Inc. (TXG) Stock Analysis and Metrics

10x Genomics

NASDAQ: TXG

$46.27 ▼ -1.79 (-3.72%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap6.17 Bn

P/E-272.14

P/S9.65

Div. Yield0.00

Revenue Growth (1y) (Qtr)-2.61

Add ratio to table…

About

10x Genomics, Inc. is a life sciences technology company that develops instruments, consumables and software to enable high resolution and large scale biological analysis. The company’s mission is to accelerate the mastery of biology to advance human health. Its product portfolio includes the Chromium single cell platform, the Visium and Xenium spatial platforms and a suite of analysis software.

The company generates revenue primarily from the sale of its instruments, consumable reagents and software licenses. For the fiscal year ended December 31, 2025, total revenue was $642.8 million, representing a 5% increase from $610.8 million in the prior year. During 2025, 10x Genomics shipped 1,007 instruments and 424,000 consumable reactions, compared with 1,073 instruments and 357,100 reactions in 2024. Sales are made through a direct sales force in North America and parts of Europe and through third party distributors in other regions. No single customer accounted for more than 10% of total revenue in either year.

The company operates through the following segments.

• Single Cell: This segment includes the Chromium platform with microfluidic chips and related consumables, the Chromium X Series and legacy Chromium instruments, and the QuantumScale Single Cell RNA and Methylation kits obtained from the acquisition of Scale Biosciences, enabling gene expression, protein, chromatin and immune repertoire profiling.

• Spatial: This segment comprises the Visium platform that uses spatial barcoding on array slides to map transcriptomic data, the Visium CytAssist instrument for streamlined workflow, and the Xenium platform for in situ analysis that detects hundreds of RNA targets directly in tissue sections using circularizable probes and fluorescence imaging without sequencing.

• Software: This segment provides the Cell Ranger pipeline for processing single cell data, Loupe Browser for interactive visualization of single cell and spatial data, Xenium Explorer for in situ data exploration, and additional tools that support experiment planning, data analysis and workflow integration across the company’s platforms.

The life sciences research tools market is estimated at approximately $75 billion annually, with 10x Genomics addressing a total addressable market of more than $21 billion. Its serviceable addressable market is estimated at over $13 billion based on current adoption of single cell, spatial and adjacent techniques. The company differentiates itself through proprietary microfluidic chemistry, barcoding chemistry and integrated hardware and software solutions. A strong intellectual property portfolio, including over 1,500 issued patents, provides protection for its core technologies. Competitors include established life sciences tools companies and emerging firms focused on single cell, spatial and in situ analysis. 10x Genomics emphasizes high throughput, reproducibility and ease of use to maintain its competitive edge.

The company serves a diverse customer base that includes academic research institutions, government laboratories, biopharmaceutical companies and biotechnology firms. Its direct sales organization operates in North America and selected European countries, while distributors cover Asia, Oceania, Latin America, the Middle East and Africa. As of December 31, 2025, the commercial organization consisted of 473 full time employees dedicated to sales, marketing and support. No single customer, including distributors, represented greater than 10% of revenue in 2025 or 2024.

Investment Thesis

▲ Bull case

10x Genomics is strategically positioned to capitalize on the structural growth of AI-driven biology, where the launch of Atara addresses a critical bottleneck in generating the high-quality, large-scale datasets required for next-generation foundation models. The company’s partnerships with initiatives like the Chan Zuckerberg Biohub’s $100 million virtual biology project and Biooptimus’s Stella program demonstrate tangible traction in building the data backbone for AI models of human tissue across global populations. This is not speculative hype but a concrete shift in research priorities, where funding is increasingly directed toward generating multimodal, spatially resolved molecular atlases—exactly the data type Atara uniquely delivers at scale. Unlike legacy platforms, Atara’s ability to process up to 3,000 whole transcriptome samples annually per instrument, combined with onboard GPU-accelerated image processing, enables throughput that was previously unattainable, turning spatial biology from a niche tool into a primary engine for discovery. The market is underestimating how rapidly AI models will saturate current data limitations and create a step-function increase in demand for the precise, context-rich data 10x Genomics produces. Early customer feedback describing Atara as “the holy grail” and the assumption among buyers that it is a “must-have platform” signals that adoption will follow a trajectory similar to prior platform shifts—initially led by early adopters but rapidly accelerating as proof points accumulate in high-impact publications and translational studies. This structural tailwind is reinforced by the company’s disciplined financial management, which has grown its cash balance by over $100 million in the past year despite macro headwinds, providing ample runway to fund Atara’s production ramp and R&D roadmap without dilutive financing. The guidance for 2026 revenue of $600–625 million, representing 0–4% ex-settlement growth, is intentionally conservative and factors in expected customer pause on legacy spatial purchases ahead of Atara shipments—a dynamic that will reverse sharply in Q4 2026 and throughout 2027 as instruments begin shipping and placements scale. The bull case hinges on the recognition that Atara is not merely an incremental product but a platform redefinition that expands the total addressable market across discovery, translational research, and AI applications simultaneously, with each segment reinforcing the others through shared data generation and workflow integration.
The company’s operating discipline has created a resilient financial foundation that is being overlooked amid near-term revenue volatility. Excluding the one-time patent litigation benefit in Q1 2025, operating expenses declined 20% year-over-year in Q1 2026, driven by sustained cost control in both R&D and SG&A, while gross margin expanded to 70% from 68% due to lower warranty costs and inventory write-downs. This improvement occurred despite ongoing investments in Atara’s launch and platform roadmap, indicating that the business model is becoming inherently more efficient as scale increases and legacy product costs are optimized. The CFO’s commentary that OpEx will be “roughly flat” year-over-year going forward—despite continued innovation spending—suggests that the company has reached an inflection point where operating leverage is beginning to manifest. This is further supported by the sequential improvement in operating loss, which narrowed from $39.3 million to $17.0 million year-over-year, even as revenue faced a temporary 3% decline due to the absence of the prior-year settlement. The company ended Q1 with $540 million in cash and marketable securities, up $113 million year-over-year, providing a buffer that exceeds two years of current operating burn at the quarterly run rate. This financial strength allows 10x Genomics to weather the anticipated Q2–Q3 sequential dip in spatial instrument revenue as customers wait for Atara, without compromising long-term investment in AI-enabled workflow automation, protein multiomics, and 10x Cloud enhancements—all of which are designed to increase customer stickiness and lifetime value. The market is failing to appreciate that the current macro environment, while constraining capital equipment spending broadly, is actually creating a selective advantage for 10x Genomics: customers with established budgets and grant funding are prioritizing Atara as a strategic, multi-year investment, and the company’s ability to secure preorders ahead of initial shipments demonstrates that demand is being pulled forward rather than delayed indefinitely. The combination of improving unit economics, a fortified balance sheet, and a product cycle aligned with secular trends in AI and translational biology creates a setup where near-term weakness is a precursor to accelerated, profitable growth.

10x Genomics is strategically positioned to capitalize on the structural growth of AI-driven biology, where the launch of Atara addresses a critical bottleneck in generating the high-quality, large-scale datasets required for next-generation foundation models. The company’s partnerships with initiatives like the Chan Zuckerberg Biohub’s $100 million virtual biology project and Biooptimus’s Stella program demonstrate tangible traction in building the data backbone for AI models of human tissue across global populations. This is not speculative hype but a concrete shift in research priorities, where funding is increasingly directed toward generating multimodal, spatially resolved molecular atlases—exactly the data type Atara uniquely delivers at scale. Unlike legacy platforms, Atara’s ability to process up to 3,000 whole transcriptome samples annually per instrument, combined with onboard GPU-accelerated image processing, enables throughput that was previously unattainable, turning spatial biology from a niche tool into a primary engine for discovery. The market is underestimating how rapidly AI models will saturate current data limitations and create a step-function increase in demand for the precise, context-rich data 10x Genomics produces. Early customer feedback describing Atara as “the holy grail” and the assumption among buyers that it is a “must-have platform” signals that adoption will follow a trajectory similar to prior platform shifts—initially led by early adopters but rapidly accelerating as proof points accumulate in high-impact publications and translational studies. This structural tailwind is reinforced by the company’s disciplined financial management, which has grown its cash balance by over $100 million in the past year despite macro headwinds, providing ample runway to fund Atara’s production ramp and R&D roadmap without dilutive financing. The guidance for 2026 revenue of $600–625 million, representing 0–4% ex-settlement growth, is intentionally conservative and factors in expected customer pause on legacy spatial purchases ahead of Atara shipments—a dynamic that will reverse sharply in Q4 2026 and throughout 2027 as instruments begin shipping and placements scale. The bull case hinges on the recognition that Atara is not merely an incremental product but a platform redefinition that expands the total addressable market across discovery, translational research, and AI applications simultaneously, with each segment reinforcing the others through shared data generation and workflow integration.
The company’s operating discipline has created a resilient financial foundation that is being overlooked amid near-term revenue volatility. Excluding the one-time patent litigation benefit in Q1 2025, operating expenses declined 20% year-over-year in Q1 2026, driven by sustained cost control in both R&D and SG&A, while gross margin expanded to 70% from 68% due to lower warranty costs and inventory write-downs. This improvement occurred despite ongoing investments in Atara’s launch and platform roadmap, indicating that the business model is becoming inherently more efficient as scale increases and legacy product costs are optimized. The CFO’s commentary that OpEx will be “roughly flat” year-over-year going forward—despite continued innovation spending—suggests that the company has reached an inflection point where operating leverage is beginning to manifest. This is further supported by the sequential improvement in operating loss, which narrowed from $39.3 million to $17.0 million year-over-year, even as revenue faced a temporary 3% decline due to the absence of the prior-year settlement. The company ended Q1 with $540 million in cash and marketable securities, up $113 million year-over-year, providing a buffer that exceeds two years of current operating burn at the quarterly run rate. This financial strength allows 10x Genomics to weather the anticipated Q2–Q3 sequential dip in spatial instrument revenue as customers wait for Atara, without compromising long-term investment in AI-enabled workflow automation, protein multiomics, and 10x Cloud enhancements—all of which are designed to increase customer stickiness and lifetime value. The market is failing to appreciate that the current macro environment, while constraining capital equipment spending broadly, is actually creating a selective advantage for 10x Genomics: customers with established budgets and grant funding are prioritizing Atara as a strategic, multi-year investment, and the company’s ability to secure preorders ahead of initial shipments demonstrates that demand is being pulled forward rather than delayed indefinitely. The combination of improving unit economics, a fortified balance sheet, and a product cycle aligned with secular trends in AI and translational biology creates a setup where near-term weakness is a precursor to accelerated, profitable growth.

▼ Bear case

10x Genomics faces significant near-term revenue headwinds due to customer purchasing delays ahead of the Atara launch, a dynamic that is being inadequately priced into current expectations despite explicit guidance acknowledging the impact. The company anticipates a step-down in Q2 and Q3 revenue as customers defer purchases of existing spatial instruments like Xenium in anticipation of Atara, with CFO Adam Taich confirming that Q2 will see a low single-digit sequential decline and Q3 remaining broadly similar—a trend directly tied to the product launch timing and not macroeconomic weakness alone. This creates a tangible air pocket in the instrument revenue line, which declined 24% year-over-year in Q1 and is expected to worsen before recovering in Q4 when initial Atara shipments begin. While management highlights strong preorder interest, the conversion of enthusiasm into actual installed base and recurring consumables revenue is contingent on successful manufacturing ramp, and the company itself admits that initial production capacity for Atara will be limited in 2026. The risk is not merely delayed revenue but a potential mismatch between demand signaling and fulfillment capability—if early adopters encounter supply constraints or performance issues during early access, the momentum could falter, leaving the company with elevated inventory, underutilized R&D spend, and a damaged perception of execution. Furthermore, the gross margin expansion to 70% in Q1 was driven by non-recurring benefits (lower warranty costs and inventory write-downs), not sustainable operational improvements, and the CFO explicitly warned that Atara’s instrument margins will come in below the portfolio average, creating dilution pressure as the platform ramps in Q4. The market may be overestimating the speed at which Atara will displace legacy platforms like Xenium and Visium, especially given customer stickiness to established workflows and the significant retraining and validation required for a wholly new system.
The company’s reliance on AI-driven biology as a structural tailwind remains speculative and unproven in terms of monetizable revenue, with near-term applications still confined to exploratory research collaborations rather than commercial, scalable deployments. While partnerships with entities like the Chan Zuckerberg Initiative, Arc Institute, and Biooptimus are strategically aligned, they represent early-stage, often non-revenue-generating efforts focused on building public data assets or proof-of-concept models—not recurring instrument or consumables sales. The CEO’s acknowledgment that AI was “a relatively low percentage of revenue” last quarter, coupled with vague descriptions of its pervasive use across customer applications, suggests that the commercialization pathway from AI research to paid platform adoption is longer and less certain than implied. There is a growing risk that the hype around AI in biology outpaces actual budget allocation, particularly as biopharma companies face their own macro pressures and may prioritize lower-cost, established technologies over novel platforms like Atara for clinical trial integration. Additionally, the spatial biology market remains nascent and fragmented, with competing technologies (including emerging in situ sequencing and multiplexed imaging approaches) potentially eroding 10x Genomics’ first-mover advantage if Atara fails to deliver on its promised sensitivity, specificity, and ease of use at scale. The company’s historical dependence on a limited number of large accounts—evident in the geographic revenue concentration and customer engagement patterns—means that a slowdown in adoption by a few key translational or AI-focused accounts could disproportionately impact results. Finally, the continued decline in Chromium instrument revenue (-12% year-over-year in Q1) and the lack of clear growth drivers beyond FLEX Apex in single cell suggest that the legacy business is maturing faster than new platforms can replace it, creating a revenue gap that Atara may not fill quickly enough to sustain overall growth.

10x Genomics faces significant near-term revenue headwinds due to customer purchasing delays ahead of the Atara launch, a dynamic that is being inadequately priced into current expectations despite explicit guidance acknowledging the impact. The company anticipates a step-down in Q2 and Q3 revenue as customers defer purchases of existing spatial instruments like Xenium in anticipation of Atara, with CFO Adam Taich confirming that Q2 will see a low single-digit sequential decline and Q3 remaining broadly similar—a trend directly tied to the product launch timing and not macroeconomic weakness alone. This creates a tangible air pocket in the instrument revenue line, which declined 24% year-over-year in Q1 and is expected to worsen before recovering in Q4 when initial Atara shipments begin. While management highlights strong preorder interest, the conversion of enthusiasm into actual installed base and recurring consumables revenue is contingent on successful manufacturing ramp, and the company itself admits that initial production capacity for Atara will be limited in 2026. The risk is not merely delayed revenue but a potential mismatch between demand signaling and fulfillment capability—if early adopters encounter supply constraints or performance issues during early access, the momentum could falter, leaving the company with elevated inventory, underutilized R&D spend, and a damaged perception of execution. Furthermore, the gross margin expansion to 70% in Q1 was driven by non-recurring benefits (lower warranty costs and inventory write-downs), not sustainable operational improvements, and the CFO explicitly warned that Atara’s instrument margins will come in below the portfolio average, creating dilution pressure as the platform ramps in Q4. The market may be overestimating the speed at which Atara will displace legacy platforms like Xenium and Visium, especially given customer stickiness to established workflows and the significant retraining and validation required for a wholly new system.
The company’s reliance on AI-driven biology as a structural tailwind remains speculative and unproven in terms of monetizable revenue, with near-term applications still confined to exploratory research collaborations rather than commercial, scalable deployments. While partnerships with entities like the Chan Zuckerberg Initiative, Arc Institute, and Biooptimus are strategically aligned, they represent early-stage, often non-revenue-generating efforts focused on building public data assets or proof-of-concept models—not recurring instrument or consumables sales. The CEO’s acknowledgment that AI was “a relatively low percentage of revenue” last quarter, coupled with vague descriptions of its pervasive use across customer applications, suggests that the commercialization pathway from AI research to paid platform adoption is longer and less certain than implied. There is a growing risk that the hype around AI in biology outpaces actual budget allocation, particularly as biopharma companies face their own macro pressures and may prioritize lower-cost, established technologies over novel platforms like Atara for clinical trial integration. Additionally, the spatial biology market remains nascent and fragmented, with competing technologies (including emerging in situ sequencing and multiplexed imaging approaches) potentially eroding 10x Genomics’ first-mover advantage if Atara fails to deliver on its promised sensitivity, specificity, and ease of use at scale. The company’s historical dependence on a limited number of large accounts—evident in the geographic revenue concentration and customer engagement patterns—means that a slowdown in adoption by a few key translational or AI-focused accounts could disproportionately impact results. Finally, the continued decline in Chromium instrument revenue (-12% year-over-year in Q1) and the lack of clear growth drivers beyond FLEX Apex in single cell suggest that the legacy business is maturing faster than new platforms can replace it, creating a revenue gap that Atara may not fill quickly enough to sustain overall growth.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password